New hope for patients with Treatment-Resistant autoimmune disease
NCT ID NCT04871191
First seen Apr 03, 2026 · Last updated Apr 07, 2026 · Updated 1 time
Summary
This study aims to find the best treatment for patients with granulomatosis with polyangiitis (GPA), a serious autoimmune disease, when standard therapies have failed. It will compare three different drug strategies involving combinations of medications like rituximab, tocilizumab, and tofacitinib. The goal is to help patients achieve remission and reduce their need for steroid medications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital de la Croix Saint Simon
RECRUITINGParis, 75020, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.